Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04308720 · ClinicalTrials.gov registry record

Circulating Tumor DNA and Immunophenotyping as Potential Biomarkers With Regional Nodal Irradiation for Breast Cancer

A clinical trial of Breast Cancer, sponsored by Mayo Clinic.

Active
Registry status
217
Enrollment target
1
Study location

NCT04308720: Active study of Breast Cancer, sponsored by Mayo Clinic.

NCT04308720 is a study of Breast Cancer that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 217 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT04308720, a study of Breast Cancer, is active but no longer recruiting, sponsored by Mayo Clinic.

ACTIVE NOT RECRUITING
Registry status
217 participants
Enrollment target
1
Study location

Study Summary

This study will assess how radiation affects the patterns of circulating tumor deoxyribonucleic acid (ctDNA) and immune cells (T cells) during radiation treatment in patients with breast cancer. By better understanding how radiation therapy affects these markers (characteristic that is measured to see how well the body responds to a treatment for a disease) in the blood, researchers may better customize treatments for patients with breast cancer in the future.

Primary Outcome

Assessed by the number of patients who have undetectable ctDNA post-treatment, among patients that were detectable pre-treatment.

Conditions Studied

Breast Cancer

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 217 participants
Start Date 2019-10-01
Est. Completion 2028-10-20
Mayo Clinic

2,844 total trials

What the registry record for NCT04308720 still lists

NCT04308720 is an observational study that tracks outcomes without assigning an intervention. The registered 217 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT04308720 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT04308720 about?

NCT04308720 is a clinical study titled "Circulating Tumor DNA and Immunophenotyping as Potential Biomarkers With Regional Nodal Irradiation for Breast Cancer". This study will assess how radiation affects the patterns of circulating tumor deoxyribonucleic acid (ctDNA) and immune cells (T cells) during radiation treatment in patients with breast cancer. By better understanding how radiation therapy affects these markers (characteristic that is measured to s...

What is the current status of trial NCT04308720?

This trial is currently active not recruiting. The enrollment target is 217 participants. The study started on 2019-10-01. Estimated completion is 2028-10-20.

What conditions does trial NCT04308720 study?

This clinical trial studies the following conditions: Breast Cancer.

Who is sponsoring clinical trial NCT04308720?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04308720 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04308720's enrollment target sits among peer trials

217 346th of 1224 higher than 878 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05079282 · 217 participants · Phase 1

    Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

  • NCT05470439 · 217 participants · NA

    My Interprofessional Care Team for Adherence and Research Engagement Disparities

  • NCT05981703 · 217 participants · Phase 1

    A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

  • NCT06342258 · 217 participants · Phase 1

    COES: Curing Order Effects on Sealants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04308720, the US trial registry maintained by the National Library of Medicine. NCT04308720 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.